西格列汀治疗新诊断2型糖尿病患者临床观察  

Clinical observation of sitagliptin in the treatment of newly diagnosed type 2 diabetes

作　　者：周岩[1] 宋菲菲[1] 吴大方[1] 曹晋[1] 

机构地区：[1]解放军451医院内分泌科,西安710054

出　　处：《西北药学杂志》2013年第4期414-416,共3页Northwest Pharmaceutical Journal

摘　　要：目的评价西格列汀治疗新诊断2型糖尿病的疗效。方法将84例新诊断2型糖尿病患者随机分为2组,治疗组42例,治疗组用西格列汀进行治疗,对照组42例应用二甲双胍治疗,观察12周。比较2组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)、体质量指数(BMI)的变化。结果治疗12周后,治疗组与对照组的FBG,2hPG,HbA1C和BMI均下降(P<0.05),西格列汀组较对照组治疗后各项指标组间差异不明显(P>0.05),但西格列汀组满意度更高。结论西格列汀控制新诊断2型糖尿病疗效确切,具有很好的降糖效果和依从性。Objective To evaluate the efficacy and safety of sitagliptin in newly diagnosed type 2 diabetes patients. Method 84 newly diagnosed T2DM patients were divided randomly in to two groups, receiving sitagliptin group and metformin control group for 12 weeks. Result After treated 12 weeks,FPG,2 h PG, HbA1C and BMI in 2 groups were decreased than before （P〈0.05） ; there were no statistical difference between the sitagliptin and the control group（P〈0.05）. Conclusion Sitagliptin could control the glycemia effectively in newly diagnosed T2DM patients, and could achieve better benefit in reducing BMI and patient-based compliance.

关 键 词：西格列汀 新诊断 2型糖尿病 

分 类 号：R977[医药卫生—药品]